jili slot demo

Maha's 'historic' verdict signifies public approval for BJP’s good governance: PM Modi

Climate change threatens global food supply: Scientists call for urgent action

Dec 5 (Reuters) - The Washington Supreme Court on Thursday gave the green light to a pilot initiative that would relax rules on who can deliver legal services in the state. Chief Justice Steven González signed an order , opens new tab that allows the court's practice of law board and the state bar association to develop the project. Under the plan , approved companies and organizations other than law firms would be able to practice law using non-traditional business models and technology, bending existing legal practice rules in a test period lasting up to a decade. The proposal got mixed reactions in September public comments , opens new tab solicited by the law practice board and bar association, with some questioning whether it could invite abuses by companies motivated by profit. The state bar association did not immediately respond to a request for comment. Washington and other states generally allow only lawyers to practice law, own law firms and share legal fees. Arizona and Utah have spearheaded their own initiatives to ease such rules, while efforts in states such as California and Florida have stalled or failed in recent years. Most recently, the Indiana Supreme Court in October directed a court-created innovation committee to "develop initial parameters for a legal regulatory sandbox" and submit them to the court for approval by March 1. Supporters generally argue that loosening barriers for entrepreneurs and other non-lawyers to hold a stake in providing legal services can make legal advice more affordable, spur innovation and expand access to justice. Critics counter that the changes could lead to abuses if providers are not fully bound by professional ethics rules that licensed lawyers must obey. The Washington order said the initiative would end 10 years after the first company was approved, and data will be collected from participants to help assess whether to adopt permanent regulatory changes. Sign up here. Reporting by Sara Merken Our Standards: The Thomson Reuters Trust Principles. , opens new tab Thomson Reuters Sara Merken reports on the business of law, including legal innovation and law firms in New York and nationally.‘Rigging is a crime’: Jake Paul’s scathing response to ‘insulting’ rumours after Mike Tyson fightOSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan ; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada ; CEO: Clarissa Desjardins; "Congruence") to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, RevenirTM. Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, RevenirTM. Ono will obtain an exclusive option right to develop, manufacture and commercialize the identified small molecule correctors worldwide. Congruence will be eligible to receive an upfront payment, research expenses, milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales. "We believe that this collaboration with Congruence may help generating novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology, leading to our development pipeline," said Seishi Katsumata , Corporate Officer / Executive Director, Discovery & Research of Ono. "We will be committed to delivering innovative new drugs to cancer patients as soon as possible." "Congruence is thrilled to partner with Ono, which has established itself as a global leader in drug development, particularly in the oncology space. We believe that our RevenirTM platform and capabilities in protein dynamics will accelerate the discovery of novel therapies for compelling targets of interest to both companies," said Sharath Hegde PhD, Chief Scientific Officer of Congruence. About RevenirTM Drug Discovery Platform RevenirTM, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, RevenirTM predicts small molecule induced correction of the underlying defect. About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Congruence's proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. For more information, please visit www.congruencetx.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/ono-enters-into-drug-discovery-collaboration-agreement-with-congruence-therapeutics-to-generate-novel-small-molecule-correctors-in-the-oncology-area-302324452.html SOURCE Ono Pharmaceutical co., ltd.

A chilling episode of 24 Hours in Police Custody will detail the nightmare a young couple faced at the hands of a cyber stalker. In the episode, which airs tonight (November 25) and aligns with White Ribbon Day – the international campaign to eliminate male violence against women and girls - the harrowing extent of cyber stalking is explored as detectives delve into the case of Daniel Dugdale and Megan Brailsford. They couple was subjected to a terrifying ordeal, including anonymous online death threats, false murder accusations leading to armed police arriving at their door, and constant surveillance that left them living in fear. The programme titled "The Murder Messages" unveills a complex web of deceit and danger, shining a light on the often-underestimated crime of stalking. As part of White Ribbon Day's message and the 16 Days of Action Against Domestic Abuse, it serves as a stark reminder of the unsettling reality some face daily and how crucial it is for such crimes to be addressed seriously by authorities. The campaign's theme this year, #ItStartsWithMe(n), calls on men specifically to confront and challenge misogyny and predatory actions to protect women and girls from abuse. Over the next 16 days, Cambridgeshire police will be supporting a campaign by sharing a wealth of information on their social media platforms about how to report abuse and what support is available locally. In the last 10 months, the force has recorded an alarming 13,079 domestic abuse incidents, marking a 2.7 per cent increase from the previous year, with women making up 72 per cent of the victims, reports Cambridgeshire Live . Detective Inspector Alicia Yorke, who leads the tactical response to domestic abuse at Cambridgeshire police, said: "I would like to thank the victim of this stalking ordeal, who went on to support the investigation as well as sharing their story on 24 Hours in Police Custody. We cannot underestimate the huge impact stalking has on victims and how, when not dealt with appropriately, it can escalate and put them in great danger." The detective stressed: "This programme really demonstrates what victims go through and I hope it empowers others to come forward and report concerns. White Ribbon Day is a chance for men to reflect on what changes they can make to ensure women and girls are safer." She continued: "While both women and men experience incidents of domestic abuse, women are far more likely than men to experience all forms of abuse, including coercive control, physical and sexual violence. The force, along with its partners, is wholly committed to ensuring women and girls are safe and feel safe by tackling violence, intimidation and harassment. We urge anyone affected by violence to come forward safe in the knowledge they will be fully supported." 24 Hours in Police Custody airs tonight at 9pm on Channel 4 and again at 10pm on Channel 4+1. Looking for more from MyLondon? Subscribe to our daily newsletters here for the latest and greatest updates from across London.Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area

Innovations In Restaurant Hood Systems Are Transforming Commercial KitchensMultibillion-dollar plan to convert coal into ‘clean’ hydrogen falters

ANNAPOLIS, Md. (AP) — Johnny Zuagar said he tried to hide his worries about a potential government shutdown from his three boys as he weighed how much to spend on Christmas presents. “I’ve got to keep a poker face,” Zuagar, a statistician at the U.S. Census Bureau, said when thinking about his boys, ages 14, 12 and 6. “You’re just trying to take that worry off of your family.” Like thousands of federal workers, Zuagar had been navigating the holidays with the spirit of the season overtaken by an air of gloom and uncertainty. The efforts in Congress to reach an agreement on keeping the government open had cast a cloud over the holidays for many federal workers facing the prospect of furloughs in the days before Christmas. But Congress passed a three-month spending bill early Saturday, just after the midnight deadline, and President Joe Biden signed it into law hours later. There was no shutdown. Many federal workers were already anxious about the possibility of future workforce reductions under the incoming Trump administration. Zuagar, who is president of the American Federation of Government Employees Local 2782, which represents federal workers at the census, has lived through shutdowns before. This time, the uncertainty came as Trump and his allies have promised sweeping cuts in the federal workforce. “We really don’t know anymore," Zuagar said during a telephone interview Friday. “Again, the rhetoric out there is that federal employees are the problem.” The contentiousness of the current debate has left him wondering: "Are we the scapegoat for every ill and grievance in America?" He said federal workers are also worried about what will happen after Trump takes office. “They’re fearful of what’s to come, like this is the beginning of something, or they don’t care about us," Zuagar said. Jesus Soriano, president of the AFGE Local 3403 representing workers at the National Science Foundation and several other agencies, also said the budget clash felt different this time around. “Americans need to decide what type of services the government should provide, whether we are talking about national security, the safety of our borders, the safety of our food, Social Security or others," Soriano said in an interview in Chevy Chase, Maryland.OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan ; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada ; CEO: Clarissa Desjardins; "Congruence") to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, RevenirTM. Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, RevenirTM. Ono will obtain an exclusive option right to develop, manufacture and commercialize the identified small molecule correctors worldwide. Congruence will be eligible to receive an upfront payment, research expenses, milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales. "We believe that this collaboration with Congruence may help generating novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology, leading to our development pipeline," said Seishi Katsumata , Corporate Officer / Executive Director, Discovery & Research of Ono. "We will be committed to delivering innovative new drugs to cancer patients as soon as possible." "Congruence is thrilled to partner with Ono, which has established itself as a global leader in drug development, particularly in the oncology space. We believe that our RevenirTM platform and capabilities in protein dynamics will accelerate the discovery of novel therapies for compelling targets of interest to both companies," said Sharath Hegde PhD, Chief Scientific Officer of Congruence. About RevenirTM Drug Discovery Platform RevenirTM, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, RevenirTM predicts small molecule induced correction of the underlying defect. About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Congruence's proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. For more information, please visit www.congruencetx.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/ono-enters-into-drug-discovery-collaboration-agreement-with-congruence-therapeutics-to-generate-novel-small-molecule-correctors-in-the-oncology-area-302324452.html SOURCE Ono Pharmaceutical co., ltd.